Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acute megakaryoblastic leukemia

W Gassmann1, H Löffler

  • 12nd Department of Internal Medicine, Christian-Albrechts-University of Kiel, Germany.

Leukemia & Lymphoma
|January 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.

Leukemia·2017
Same author

Mutations in the sodium channel gene SCN2A cause neonatal epilepsy with late-onset episodic ataxia.

Journal of neurology·2015
Same author

Contact allergy induced by bisphenol A diglycidyl ether leachables from aluminium tubes for pharmaceutical use.

Allergy·2015
Same author

Skin irritability to sodium lauryl sulfate is associated with increased positive patch test reactions.

The British journal of dermatology·2014
Same author

[Cancer of unknown primary. Epidemiology and pathogenesis].

Der Radiologe·2014
Same author

[Structured diagnostics and therapy of the CUP syndrome].

Der Radiologe·2014
Same journal

CPX‑351 vs. FLAG‑ida in patients with high-risk AML/MDS and MDS-related gene mutations: a subgroup analysis of the UK NCRI AML19 trial.

Leukemia & lymphoma·2026
Same journal

Specialist palliative care access and end-of-life hospitalizations in acute leukemia: a nationwide register study.

Leukemia & lymphoma·2026
Same journal

D-VRD vs. D-KRD induction in transplant-eligible multiple myeloma: a real-world comparison.

Leukemia & lymphoma·2026
Same journal

T-box factor EOMES is part of an aberrant network in Hodgkin lymphoma.

Leukemia & lymphoma·2026
Same journal

Overall survival of patients with chronic lymphocytic leukemia treated with venetoclax-obinutuzumab compared to age- and sex-matched general population.

Leukemia & lymphoma·2026
Same journal

Hypertension and time to treatment failure with acalabrutinib and ibrutinib in treatment-naïve CLL/SLL.

Leukemia & lymphoma·2026
See all related articles

Acute megakaryoblastic leukemia (AML M7) diagnosis requires over 30% megakaryoblasts in bone marrow. Immunophenotyping is crucial to confirm AML M7 and differentiate it from other leukemias, as morphology alone can be misleading.

Area of Science:

  • Hematology
  • Oncology
  • Cell Biology

Background:

  • Acute megakaryoblastic leukemia (AML M7) is a subtype of acute myeloid leukemia.
  • It affects all age groups, with notable peaks in adults and children aged 1-3, particularly those with Down's syndrome.
  • Diagnosis requires over 30% megakaryoblasts in nucleated bone marrow cells.

Purpose of the Study:

  • To outline the diagnostic criteria for AML M7.
  • To emphasize the importance of immunophenotyping in differentiating AML M7 from other leukemias.
  • To describe the morphological spectrum of megakaryoblastic leukemias.

Main Methods:

  • Morphological and cytochemical analysis to exclude AML MO-M6.
  • Immunological analysis (e.g., CD61, CD42, CD41) to confirm megakaryocytic lineage and exclude acute lymphoblastic leukemia (ALL).

Related Experiment Videos

  • Ultrastructural demonstration of platelet peroxidase for diagnosis.

    • Main Results:

    • AML M7 diagnosis is confirmed by >30% megakaryoblasts.
    • Morphological features can be variable, ranging from small to large cells with distinct cytoplasmic and nuclear characteristics.
    • Immunophenotyping is essential as morphology can mimic other conditions like common acute lymphoblastic leukemia (c-ALL).

    Conclusions:

    • Accurate diagnosis of AML M7 relies on a combination of morphology, cytochemistry, and crucially, immunophenotyping.
    • Cytochemistry has limited value for definitive AML M7 diagnosis but aids in excluding other AML subtypes.
    • Immunological markers are indispensable for confirming megakaryocytic differentiation and distinguishing AML M7 from morphologically similar leukemias.